JP2010520290A5 - - Google Patents

Download PDF

Info

Publication number
JP2010520290A5
JP2010520290A5 JP2009552761A JP2009552761A JP2010520290A5 JP 2010520290 A5 JP2010520290 A5 JP 2010520290A5 JP 2009552761 A JP2009552761 A JP 2009552761A JP 2009552761 A JP2009552761 A JP 2009552761A JP 2010520290 A5 JP2010520290 A5 JP 2010520290A5
Authority
JP
Japan
Prior art keywords
epha3
antibody
pharmaceutical composition
composition according
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009552761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520290A (ja
JP5311060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003149 external-priority patent/WO2008112192A2/en
Publication of JP2010520290A publication Critical patent/JP2010520290A/ja
Publication of JP2010520290A5 publication Critical patent/JP2010520290A5/ja
Application granted granted Critical
Publication of JP5311060B2 publication Critical patent/JP5311060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009552761A 2007-03-08 2008-03-10 固形腫瘍の治療のためのＥｐｈＡ３抗体 Active JP5311060B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89384807P 2007-03-08 2007-03-08
US60/893,848 2007-03-08
PCT/US2008/003149 WO2008112192A2 (en) 2007-03-08 2008-03-10 Epha3 antibodies for the treatment of solid tumors

Publications (3)

Publication Number Publication Date
JP2010520290A JP2010520290A (ja) 2010-06-10
JP2010520290A5 true JP2010520290A5 (index.php) 2011-04-21
JP5311060B2 JP5311060B2 (ja) 2013-10-09

Family

ID=39689392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552761A Active JP5311060B2 (ja) 2007-03-08 2008-03-10 固形腫瘍の治療のためのＥｐｈＡ３抗体

Country Status (13)

Country Link
US (1) US8637016B2 (index.php)
EP (2) EP2136838B1 (index.php)
JP (1) JP5311060B2 (index.php)
CN (1) CN101641115B (index.php)
AU (1) AU2008226905C1 (index.php)
CA (1) CA2679986C (index.php)
DK (1) DK3199180T3 (index.php)
ES (1) ES2910298T3 (index.php)
IL (1) IL200764A (index.php)
NZ (1) NZ579478A (index.php)
PL (1) PL3199180T3 (index.php)
PT (1) PT3199180T (index.php)
WO (1) WO2008112192A2 (index.php)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
JP5781762B2 (ja) 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
NZ594950A (en) * 2009-03-06 2013-06-28 Kalobios Pharmaceuticals Inc Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
PT2488554T (pt) 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
US20110243934A1 (en) * 2010-04-01 2011-10-06 Kalobios Pharmaceuticals Inc. Epha3 antibodies for the treatment of multiple myeloma
CA2802723A1 (en) * 2010-06-18 2011-12-22 Kalobios Pharmaceuticals, Inc. Detection of epha3 as a marker of the presence of a solid tumor
AU2011338425A1 (en) * 2010-12-08 2013-05-02 Stemcentrx, Inc. Novel modulators and methods of use
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
CN104254340A (zh) * 2011-08-12 2014-12-31 卡罗生物制药股份有限公司 通过靶向骨髓中异常血管系统上表达的EphA3来治疗血液增殖性疾病的方法
EP3068797B1 (en) 2013-11-11 2020-01-08 Wake Forest University Health Sciences Constructs for multi-valent targeting of tumors
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
CN112867735B (zh) 2018-09-07 2025-05-09 埃泰美德(香港)有限公司 双特异性抗原结合蛋白及其用途
JP2022552786A (ja) * 2019-10-09 2022-12-20 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 標的化ｅｐｈａ３及びその使用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
JP3955316B2 (ja) 1991-06-21 2007-08-08 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規レセプター型チロシンキナーゼ及びその用途
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1508337A3 (en) 1998-11-20 2006-04-19 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
DK1176195T3 (da) 1999-04-09 2013-06-24 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
PT1522590E (pt) 2000-06-28 2009-10-26 Glycofi Inc Métodos para a produção de glicoproteínas modificadas
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
US6652853B2 (en) * 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
US20030091574A1 (en) * 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
US20050049194A1 (en) * 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
WO2003102144A2 (en) 2002-05-29 2003-12-11 Curagen Corporation Compositions and methods of use for an ephrin rreceptor
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
ATE541857T1 (de) 2002-09-27 2012-02-15 Xencor Inc Optimierte fc-varianten und herstellungsverfahren dafür
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US8222253B2 (en) 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
CA2585717A1 (en) * 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006055778A2 (en) 2004-11-16 2006-05-26 Kalobios, Inc. Immunoglobulin variable region cassette exchange
AU2007205935B2 (en) 2006-01-17 2013-07-11 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies

Similar Documents

Publication Publication Date Title
JP2010520290A5 (index.php)
JP2015509947A5 (index.php)
JP2015509948A5 (index.php)
JP2019514844A5 (index.php)
JP2018505177A5 (index.php)
JP2018534933A5 (index.php)
JP2017529838A5 (index.php)
JP2017501711A5 (index.php)
JP2011046732A5 (index.php)
JP2016510002A5 (index.php)
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
CN110799543A (zh) 肝细胞癌的免疫治疗
ME03394B (me) Antidllз-antitelo-pbd konjugati i nihovа upotreba
JP2017535257A5 (index.php)
JP2016538318A5 (index.php)
JP2016536361A5 (index.php)
JP2009525764A5 (index.php)
JP2011506483A5 (index.php)
JP2018506277A5 (index.php)
JP2015503909A5 (index.php)
JP2006512899A5 (index.php)
JP2015533781A5 (index.php)
JP2020500834A5 (index.php)
JP2016094424A5 (index.php)
JP2013508292A5 (index.php)